NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Professor Richard Scolyer was diagnosed with glioblastoma IDH -wild type - MGMT unmethylated in June 2023.
Professor Scolyer was given two immunotherapy drugs twelve days before surgery (first patient in the world), designed to activate the immune system to attack the cancer.
They also used the specific genome of his cancer to design a vaccine to target it.
They found there was a 10-fold increase in the immune cells in the tumour, that they were activated against the cancer and they were bound to the drug.
Here is the link:

Melanoma Institute Australia Co-Medical Directors Professor Richard Scolyer and Professor Georgina Long speak on the topic 'Melanoma science in the race against brain cancer. Using a terminal diagnosis as a path for good'.

https://iview.abc.net.au/video/NC2311C034S00
https://www.abc.net.au/news/2023-09-20/melanoma-richard-scolyer-georgina-long-early-results/102879818

Standing ovation for ⁦⁦@ProfRScolyerMIA⁩ & ⁦@ProfGLongMIA⁩ after ⁦@PressClubAust⁩ address, revealing scientific breakthroughs for #glioblastoma and imploring cancer research field to think BIG and be BOLD Press Club Address : ABC iview https://t.co/cK7LCffBsp

— Melanoma Institute Australia (@MelanomaAus) September 20, 2023